Rodríguez B, Burguera J, Berenguer M

Language: English
References: 23
Page: 907-914
PDF size: 90.00 Kb.

ABSTRACT

Background and aims. There are certain areas of uncertainty regarding the best therapeutic approach in patients diagnosed with Wilson Disease (WD). Our aim was to assess treatment response to different therapies in a cohort of WD patients followed in a single center. Material and methods. This is an observational, descriptive study in which clinical, laboratory and imaging data are reviewed in a series of 20 WD patients with a median follow-up of 14 years. Type of presentation, treatment used, biochemical and copper homeostasis parameters were elicited. Results. Median age at diagnosis was 22 years. The most frequent form of presentation was hepatic (n = 10, 50%; mean age: 21.5 years), followed by neurological (25%; mean age: 34.5 years) and mixed (15%). The initial treatment in both symptomatic and asymptomatic patients at diagnosis was d-penicillamine in 90% and Zinc (Zn) in 10%, respectively. Patients who were maintained on d-penicillamine for the whole period had complete biochemical normalization (baseline ALT: 220 IU/l; last follow up 38 IU/l). In contrast, patients in whom d-penicillamine was switched to Zn, irrespective of the cause, did not show a complete biochemical remission (baseline ALT: 100 IU/l vs. 66 IU/l at last follow-up). Conclusions. Treatment was found to be effective in most cases regardless of the drug used. However, side effects were common in those treated with d-penicillamine agents, and required switching to zinc. Therapy with zinc was well tolerated and appeared to have a good efficacy. However, in 33%, a complete normalization of liver enzymes was never reached.

REFERENCES

1. SAK W. Progressive lenticular degeneration: a familiar nervous disease associated with cirrosis of the liver. Brain 1912; 34: 295-507.

2. Saito T. An assessment of efficiency in potential screening for Wilson’s disease. J Epidemiol Community Health 1981; 35: 274-80.

3. Bull PC TG, Rommens JM, Forbes JR, Cox DW. The Wilson Disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327-37.

4. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993; 197: 271-7.

5. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344-50.

6. Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype- phenotype correlation, and functional analyses. Am J Hum Genet 1997; 61: 317-28.

7. Scheinberg IH, Sternlieb I. Wilson’s Disease. Annu Rev Med 1965; 16: 119-34.

8. Brewer GJ. Recognition, diagnosis, and management of Wilson’s disease. Proc Soc Exp Biol Med 2000; 223: 39-46.

9. Sternlieb I. Diagnosis of Wilson’s disease in 1981. Gastroenterol Clin Biol 1981; 5: 169-74.

10. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139-42.

11. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007; 56: 115-20.

12. Maytum WJ, Goldstein NP, Mc GW, Owen CA Jr. Copper metabolism in Wilson’s disease, Laennec’s cirrhosis and hemachromatosis: studies with radiocopper (Cu64). Proc Staff Meet Mayo Clin 1961; 36: 641-60.

13. Saito H, Watanabe K, Sahara M, Mochizuki R, Edo K, Ohyama Y. Triethylene-tetramine (trien) therapy for Wilson’s disease. Tohoku J Exp Med 1991; 164: 29-35.

14. Walshe JM. Management of penicillamine nephropathy in Wilson’s disease: a new chelating agent. Lancet 1969; 2: 1401-2.

15. Walshe JM. Wilson’s disease; new oral therapy. Lancet 1956; 270: 25-6.

16. Hoogenraad TU, Koevoet R, de Ruyter Korver EG. Oral zinc sulphate as long-term treatment in Wilson’s disease (hepatolenticular degeneration). Eur Neurol 1979; 18: 205-11.

17. Schilsky ML, Blank RR, Czaja MJ, Zern MA, Scheinberg IH, Stockert RJ, Sternlieb I. Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest 1989; 84: 1562-8.

18. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson’s disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998; 132: 264-78.

19. Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson’s disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77: 137-46.

20. Weiss KH, Gotthardt DN, Klemm D, Merle U, Ferenci-Foerster D, Schaefer M, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011; 140: 1189-1198, e1.

21. Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson’s disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003; 142: 385-90.

22. Sen S, Felldin M, Steiner C, Larsson B, Gillett GT, Olausson M, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson’s disease. Liver Transpl 2002; 8: 962-7.

23. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47: 2089-111.